BioSpace News Archive

Angle PLC - Contract announcement with Eisai Inc.

ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell diagnostic solutions for use in research, drug development and clinical oncology, is delighted to announce that it has signed a contract with the global pharmaceutical company, Eisai Inc..

January 2, 2024
·
3 min read
Drug Development

Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate

Biotechnology company Inventprise Inc.n announced the completion of vaccination in their Phase 2 dose ranging study of its 25-valent pneumococcal conjugate vaccine in young adults.

January 2, 2024
·
4 min read
Genetown

Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024

Sage Therapeutics, Inc. announced today that the Company will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT in San Francisco, CA.

January 2, 2024
·
1 min read
Genetown

Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Neumora Therapeutics, Inc. today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Monday, January 8, 2024 at 11:15 a.m. PT (2:15 p.m. ET).

January 2, 2024
·
1 min read
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th

Zealand Pharma A/S announced that President and Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference at 10:10 a.m. ET on Thursday, January 4, 2024.

January 2, 2024
·
1 min read
Genetown

Apollo Therapeutics Announces Second Close of Series C Financing Bringing Total Raised in Round to $260 Million

Apollo Therapeutics announces that during December 2023 it completed a second close of its Series C financing, raising an additional $33.5 million and bringing the total raised in this round by the Company during 2023 to $260 million.

January 2, 2024
·
3 min read
NanoPhoria Bioscience Publishes Groundbreaking Study in Major Cardiology Journal

NanoPhoria srl, a pre-clinical stage biotech company, is pleased to announce the publication of a groundbreaking study in the field of cardiology, conducted using a clinically relevant pig model of heart failure.

January 2, 2024
·
4 min read
Mabwell to attend 42nd JP Morgan Healthcare Conference and present at Biotech Showcase

Mabwell, an innovative biopharmaceutical company with entire industry chain, announced that Dr. Hai Wu, R&D VP of Mabwell, will attend 42nd JP Morgan Healthcare Conference and present at Biotech Showcase in San Francisco, United States.

January 2, 2024
·
5 min read
Policy

Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout

ABP-745 is an oral small molecule drug that also has potential applicationsfor other anti-inflammatory diseases

January 2, 2024
·
2 min read
Biotech Beach

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company (“ImmunityBio” or the “Company”), today announced an up to $320 million royalty financing and equity investment in the Company by Oberland Capital, with $210 million of gross proceeds received at closing on December 29, 2023.

January 2, 2024
·
10 min read